Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2012

Open Access 01-12-2012 | Research article

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Authors: Daniel R Murphy, Lee J Smolen, Timothy M Klein, Robert W Klein

Published in: BMC Musculoskeletal Disorders | Issue 1/2012

Login to get access

Abstract

Background

This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study’s objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.

Methods

A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.
For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of −3.0. The GIOP cohorts simulated had an initial BMD T-Score of −2.5.

Results

The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were €36,995 per QALY and €19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were €20,826 per QALY and €15,155 per QALY, respectively.

Conclusions

The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of €50,000.
Appendix
Available only for authorised users
Literature
1.
Borgström F, Sobocki P, Ström O, Jönsson B: The societal burden of osteoporosis in Sweden. Bone. 2007, 40: 1602-1609. 10.1016/j.bone.2007.02.027.CrossRefPubMed
2.
Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B: Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000, 11: 669-674. 10.1007/s001980070064.CrossRefPubMed
3.
Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008, 19: 399-428. 10.1007/s00198-008-0560-z.CrossRefPubMedPubMedCentral
4.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001, 344: 1434-1441. 10.1056/NEJM200105103441904.CrossRefPubMed
5.
Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster J, Stepan JJ, Myers SL, Mitlak BH: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004, 164: 2024-2030. 10.1001/archinte.164.18.2024.CrossRefPubMed
6.
Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005, 20: 1507-1513. 10.1359/JBMR.050501.CrossRefPubMed
7.
Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH: The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin. 2005, 21: 1027-1034. 10.1185/030079905X49671.CrossRefPubMed
8.
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007, 357: 2028-2039. 10.1056/NEJMoa071408.CrossRefPubMed
9.
Orcel P: Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Joint Bone Spine. 2005, 72: 461-465. 10.1016/j.jbspin.2005.09.002.CrossRefPubMed
10.
van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000, 39: 1383-1389. 10.1093/rheumatology/39.12.1383.CrossRef
11.
Saag KG: Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003, 32: 135-157. 10.1016/S0889-8529(02)00064-6. viiCrossRefPubMed
12.
13.
Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M: Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007, 11: iii-iv. ix–xi, 1–231CrossRefPubMed
14.
Lundkvist J, Johnell O, Cooper C, Sykes D: Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int. 2006, 17: 201-211. 10.1007/s00198-005-1959-4.CrossRefPubMed
15.
16.
17.
Sweden South Region Health Board Healthcare Region: Regional Rates and Allowances for Southern Health Region 2011. 2010
18.
19.
Kanis JA, Borgström F, Johnell O, Oden A, Sykes D, Jönsson B: Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int. 2005, 16: 15-25. 10.1007/s00198-004-1688-0.CrossRefPubMed
20.
Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B: Mortality after osteoporotic fractures. Osteoporosis International. 2004, 15: 38-42. 10.1007/s00198-003-1490-4.CrossRefPubMed
21.
Lundberg L, Johannesson M, Isacson DGL, Borgquist L: Health-state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Pub Health. 1999, 9: 211-217. 10.1093/eurpub/9.3.211.CrossRef
22.
Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F: Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int. 2009, 85: 484-493. 10.1007/s00223-009-9299-6.CrossRefPubMedPubMedCentral
23.
Weycker D, Macarios D, Edelsberg J, Oster G: Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006, 17: 1645-1652. 10.1007/s00198-006-0179-x.CrossRefPubMed
24.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK: The components of excess mortality after hip fracture. Bone. 2003, 32: 468-73. 10.1016/S8756-3282(03)00061-9.CrossRefPubMed
25.
Lips P, van Schoor NM: Quality of life in patients with osteoporosis. Osteoporos Int. 2005, 16: 447-455. 10.1007/s00198-004-1762-7.CrossRefPubMed
26.
Schousboe JT: Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep. 2007, 9: 50-56. 10.1007/s11926-007-0022-1.CrossRefPubMed
27.
28.
Schousboe JT, Nyman JA, Kane RL, Ensrud KE: Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005, 142: 734-741.CrossRefPubMed
29.
Borgström F, Ström O, Marin F, Kutahov A, Ljunggren O: Cost effectiveness of teriparatide and PTH(1–84) in the treatment of postmenopausal osteoporosis. J Med Econ. 2010, 13: 381-392. 10.3111/13696998.2010.499072.CrossRefPubMed
30.
Peasgood T, Herrmann K, Kanis JA, Brazier JE: An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int. 2009, 20: 853-868. 10.1007/s00198-009-0844-y.CrossRefPubMed
Metadata
Title
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
Authors
Daniel R Murphy
Lee J Smolen
Timothy M Klein
Robert W Klein
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2012
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-13-213

Other articles of this Issue 1/2012

BMC Musculoskeletal Disorders 1/2012 Go to the issue

Research article

Physiotherapy movement based classification approaches to low back pain: comparison of subgroups through review and developer/expert survey

Research article

Clinimetric properties of the Turkish translation of a modified neck disability index

Study protocol

The PRESLO study: evaluation of a global secondary low back pain prevention program for health care personnel in a hospital setting. Multicenter, randomized intervention trial

Research article

Patients with low back pain differ from those who also have leg pain or signs of nerve root involvement – a cross-sectional study

Research article

Mechanical pain sensitivity of deep tissues in children - possible development of myofascial trigger points in children

Study protocol

Tenotomy versus Tenodesis in the treatment of the long head of biceps brachii tendon lesions